tbuckley/cabot-search huggingface dataset:
Abstract 2922: Prediagnostic smoking, alcohol intake, physical activity and survival after colorectal cancer diagnosis in Western European populations
Authors: Veronika Fedirko, Elio Riboli, Teresa Norat, Anne Tjønneland, Mazda Jenab
Journal: Cancer Research (2014)

Abstract Background: Cigarette smoking, high intake of alcohol, and lack of physical activity are associated with increased colorectal cancer (CRC) risk, but little research has been conducted to investigate the association between these modifiable lifestyle factors and survival after CRC diagnosis. Methods: Therefore, we prospectively assessed the association between smoking status and intensity, baseline alcohol intake, lifetime pattern of alcohol intake, physical activity and all-cause and CRC-specific death among 3,916 participants diagnosed with colorectal cancer (colon = 2,454, rectum = 1,462) between 1992 and 2008 in the EPIC cohort. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Results: There were 1,303 deaths, 1,039 (80%) due to CRC. Mean follow-up after CRC diagnosis was 4 years. In multivariable analysis, current vs. never smokers had an increased risk of all-cause death (HR = 1.22, 95% CI: 1.04-1.44). Greater intensity of smoking (26+ cigarettes per day) was associated with almost a doubling in the risk of all-cause death when compared with never smokers (HR = 1.75, 95% CI: 1.12-2.73). Alcohol consumption was not statistically significantly associated with survival (HR = 1.00, 95% CI: 0.98-1.02 per 6 g per day), however former heavy drinkers had an increased risk of all-cause death (HR = 2.68, 95% CI: 1.13-6.39). Total physical activity was not statistically significantly associated with CRC survival. Additional subgroup analyses were conducted by sex, age at diagnosis, cancer stage and grade, location of tumor, time between blood collection and cancer diagnosis, year of diagnosis, follow-up period, and body mass index. Results for CRC-specific death were similar to those reported for all-cause death. Conclusions: Our preliminary results suggest that cigarette smoking and being a former heavy drinker before cancer diagnosis are associated with worse survival among Western European patients with CRC, but further research is needed to confirm these results. Citation Format: Veronika Fedirko, Elio Riboli, Teresa Norat, Anne Tjønneland, Mazda Jenab, on behalf of the EPIC CRC Working Group. Prediagnostic smoking, alcohol intake, physical activity and survival after colorectal cancer diagnosis in Western European populations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2922. doi:10.1158/1538-7445.AM2014-2922
Q: Is the cerebellum an adaptive combiner of motor and mental/motor activities? A: Yes, maybe, certainly not, who can say?
Authors: W. Thomas Thach
Journal: Behavioral and Brain Sciences (1996)

The target article reviews studies of human cerebellar functional imaging and ablation in motor learning. This material is integrated with anatomical and physiological work in laboratory animals. A synthesis is presented as a working hypothesis on how the cerebellum might adapt, learn, and coordinate movement. An attempt is made to extend the motor role to certain mental operations, particularly those associated with mental movement. These notions met with varying enthusiasm. A few commentators seemed pleased with the overall result and offered supportive ideas. Some were critical of the proposed contributions to cognition and motor learning. A surprising number insisted that the cerebellum was more concerned with sensory processing than with movement management. Some thought we know too little to attempt such a synthesis.
Imaging Studies for Hepatobiliary Tumors
Authors: Revathy Iyer, Chusilp Charnsangavej
Journal: Liver Cancer (1998)

Surgical techniques with curative intent are becoming more common-place for both primary and metastatic tumors of the liver. The development of aggressive surgical techniques has allowed the surgeon to view a patient with a primary hepatic tumor or certain types of metastatic disease as a possible candidate for curative resection rather than as a patient with end stage disease. It is therefore important to detect and characterize hepatic lesions to determine if a patient is a surgical candidate and, if so, to plan operative strategies. It is the goal of hepatic imaging to identify and stage lesions for hepatic surgeons. The issues imaging must address include (1) whether hepatic lesions are present and, if so, how many; (2) the character of any such lesions; and (3) whether malignant tumors are resectable.1,2 These queries are now being answered more easily with advances in imaging.
1021. VP22 Mediates Tumor Vasculature Specific Targeting
Authors: Sudhanshu P. Raikwar, Thomas A. Gardner, Chinghai Kao
Journal: Molecular Therapy (2004)

Prostate cancer (CaP) is the most frequently diagnosed cancer in men and the second leading cause of cancer related deaths in American men. In 2003, CaP was expected to account for 220,900 cancer diagnoses and 28,900 cancer deaths. Despite recent advances in the early detection and treatment of locally advanced prostate cancer, the prognosis for patients with the advanced form of prostate cancer is grave. The explosion of research in the genetic and molecular events paralleling the development of the lethal form of the disease has lead to the identification of multiple therapeutic targets. Targeting the molecular mechanisms underlying CaP development and metastasis offers a novel approach towards the development of effective therapeutic modalities. As part of our long term goal the major focus of the current study was to integrate real-time intravital imaging of prostate tumor dynamics along with retroviral and adenoviral gene transfer approach for maximizing the therapeutic efficacy and bystander effect of apoptosis inducers by exploiting VP22-mediated tumor vasculature specific targeting. We have used intravital imaging for the real-time monitoring of tumor progression, angiogenesis and adenoviral mediated gene transfer in athymic nude mouse models of prostate cancer. The human prostate cancer cell lines, LNCaP, C4-2 and PC-3 were transduced with an enhanced green fluorescent protein expressing, gibbon ape leukemia virus (GALV) envelope pseudotyped retroviral vector MFG-EGFP-GALV. Flow cytometry revealed that the retroviral transduction efficiency is cell line dependent and was in the order PC-3 (72.46%)>LNCaP (44.37%)>C4-2 (34.47%). A fluorescent prostate tumor model was developed by subcutaneous injection of PC-3 cells in six weeks old, uncastrated, male athymic nude mice. The tumor bearing mice were injected with Dextran-Texas Red dye and subjected to sequential intravital imaging on days 17 and 24 using a dual photon Bio-Rad MRC-1024 microscope. Higly fluorescent EGFP expressing tumor cells were observed along with neo-vascularization of the tumor. Infiltration of Dextran-Texas Red dye in between the EGFP expressing tumor cells was observed thereby indicating leaky tumor vasculature. We have used this technique for the real time intravital imaging of Herpes simplex virus tegument protein VP22 mediated intercellular trafficking dynamics and novel tumor vasculature specific targeting in androgen dependent and androgen independent prostate tumor models following intra-tumoral as well as systemic delivery. For the very first time, we would like to report VP22-mediated tumor vasculature specific targeting while sparing the normal vasculature associated with hepatic and muscular tissues. Our striking and novel findings suggest that hybrid VP22-apoptosis inducers might act as a double edged sword by maximizing apoptosis induction and the associated bystander effect on one hand and selectively targeting the tumor vasculature destruction thereby potentiating the anti-angiogenic effects.
Abstract 1516: Automated circulating DNA purification from large volumes of plasma
Authors: Sydnor T. Withers, Mary Dressler, Cristopher A. Cowan
Journal: Cancer Research (2014)

Abstract The circulating DNA found in human plasma is enriched for genomic DNA from minority tissues such as tumors, fetuses, and transplanted tissue. This sub fraction of blood has become an area of interest for development and disease as the nucleic acid recovered may represent a source of biomarkers for study. One milliliter of plasma typically yields between 1 ng and 50 ng of DNA. The current commercial DNA purification methods limit researchers' ability to scale their samples in both volume and number. Automated solutions are not available to process large numbers of samples with volumes greater than 1 ml, and manual methods can process up to 5 ml of plasma. Here we present a fully automated solution to extract DNA from 1-64 samples up to 8 ml in volume. The system provides an intuitive user interface to select run options and enter barcodes for reagents and samples. Any combination of sample volumes may be processed together in a single run. Samples are eluted in 50 µl of nuclease-free water in either plates or tubes. We have found that the performance of our system meets or exceeds common commercial alternatives over their common sample input volume. Citation Format: Sydnor T. Withers, Mary Dressler, Cristopher A. Cowan. Automated circulating DNA purification from large volumes of plasma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1516. doi:10.1158/1538-7445.AM2014-1516
Küçük Hücreli Dışı Akciğer Kanserinde BCL-2 Ekspresyonu İyi Sağkalım İçin Belirleyicidir
Authors: Daniel J. Renouf, Richard Wood-Baker, Diana N. Ionescu, Samuel Leung, Hamid Masoudi, Cyril B. Gilks, and Janessa Laskin
Journal: Journal of Thoracic Oncology (2009)
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Authors: Tim H. Brümmendorf, Tessa L. Holyoake, Nathalie Rufer, Michael J. Barnett, Michael Schulzer, Connie J. Eaves, Allen C. Eaves, Peter M. Lansdorp
Journal: Blood (2000)
Commentary: A fairytale ending?
Authors: Domhnall Macauley
Journal: BMJ (2006)

I hadn't heard of rumination syndrome before reading Mr Neville's story. 1 My first thought on hearing about his repeated presentation, negative findings, and distress was that this was a case of somatoform disorder. 2His deterioration after a difficult meeting with a staff member supported that view.Is rumination syndrome a distinct syndrome or is it an example of a functional somatic syndrome? 3It is unfortunate that mind-body dualism still dominates clinical discussions and management.To me, this sounds like a condition with psychogenic aetiology but physical manifestation.His symptoms are not "all in the mind," they are "all in the stomach"; understandably Mr Neville and his general practitioner sought advice from gastroenterologists.
Abstract 2935: RNAi screen identifies therapeutic targets in hepatocellular carcinoma
Authors: Chun-Hao Huang, Amaia Lujambio, Johannes Zuber, Thomas Kitzing, Darjus F. Tschaharganeh, Elisa D. Stanchina, Scott W. Lowe
Journal: Cancer Research (2014)

Abstract Liver cancer is the third leading cause of cancer related mortality worldwide. Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a very aggressive type of cancer that lacks effective treatment, in part, due to the undruggable nature of its main genetic drivers, such as oncogene MYC amplification or loss of tumor suppressor TP53. The introduction of the multikinase inhibitor Sorafenib represents the biggest therapeutic advance in the past decade, though its activity only increases the life expectancy of liver cancer patients from 8 to 11 months. To identify new therapeutic targets for HCC, we employ RNA interference (RNAi) screens as a non-biased means to identify genes required for tumor maintenance in genetically defined tumors. In the current study, we applied an optimized shRNA platform to perform a negative selection screen in genetically-defined murine hepatocellular carcinoma cell in vitro. Specifically, we have designed a library that contains 2,245 shRNAs targeting 442 “drugged” genes, including genes encoding proteins targeted by FDA-approved drugs, small molecules in clinical trials, or compounds under preclinical development. Countersceening and validation was performed in normal murine cells and human HCC cell lines and xenograft using shRNAs and corresponding small molecular drugs. Pharmacological or shRNA-mediated inhibition of certain targets led to robust antitumor effects, both in vitro and in vivo, and suggest new strategies to inhibit Myc function therapeutically. Our results highlight the utility of RNAi screening for studying cancer vulnerabilities that can be exploited for direct pharmacological intervention. Citation Format: Chun-Hao Huang, Amaia Lujambio, Johannes Zuber, Thomas Kitzing, Darjus F. Tschaharganeh, Elisa De Stanchina, Scott W. Lowe. RNAi screen identifies therapeutic targets in hepatocellular carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2935. doi:10.1158/1538-7445.AM2014-2935
All doctors practising in the UK will need licence by 16 November
Authors: Clare Dyer
Journal: BMJ (2009)

All doctors will need a licence to practise medicine in the United Kingdom from November 16, the General Medical Council announced this week.

From that date it will no longer be enough for doctors just to be registered with the General Medical Council before they undertake any form of practice, whether privately or in the NHS, full time or part time, employed or self employed. They will need a licence …
Let Them Eat Fish
Authors: Vickie Baracos
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease
Authors: Andrew R.J. Curtis, Constanze Fey, Christopher M Morris, Laurence A. Bindoff, Paul G. Ince, Patrick F. Chinnery, Alan Coulthard, Margaret J. Jackson, Andrew P. Jackson, Duncan P. McHale, David Hay, William A. Barker, Alex F. Markham, David Bates, Ann Curtis, John Burn
Journal: Nature Genetics (2001)
Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma
Authors: MA Dimopoulos, R Alexanian, D Przepiorka, J Hester, B Andersson, S Giralt, R Mehra, K van Besien, KB Delasalle, C Reading
Journal: Blood (1993)
Extended diagnostic value of autologous serum skin test and basophil CD63 expression assay in chronic urticaria
Authors: B. Irinyi, E. Gyimesi, E. Garaczi, Z.S. Bata, L. Kemény, M. Zeher, E. Remenyik, A. Szegedi
Journal: British Journal of Dermatology (2012)

Journal Article Extended diagnostic value of autologous serum skin test and basophil CD63 expression assay in chronic urticaria Get access B. Irinyi, B. Irinyi Departments of DermatologyDermatological Allergology Search for other works by this author on: Oxford Academic Google Scholar E. Gyimesi, E. Gyimesi Division of Clinical Immunology, 3rd Department of Internal Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary Edit Gyimesi. E‐mail:egyimesi@freemail.hu Search for other works by this author on: Oxford Academic Google Scholar E. Garaczi, E. Garaczi Department of Dermatology and Allergology, University of Szeged, Albert Szent‐Györgyi Medical and Pharmaceutical Center, Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar Z.S. Bata, Z.S. Bata Department of Dermatology and Allergology, University of Szeged, Albert Szent‐Györgyi Medical and Pharmaceutical Center, Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar L. Kemény, L. Kemény Department of Dermatology and Allergology, University of Szeged, Albert Szent‐Györgyi Medical and Pharmaceutical Center, Szeged, Hungary Search for other works by this author on: Oxford Academic Google Scholar M. Zeher, M. Zeher Division of Clinical Immunology, 3rd Department of Internal Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary Search for other works by this author on: Oxford Academic Google Scholar E. Remenyik, E. Remenyik Departments of Dermatology Search for other works by this author on: Oxford Academic Google Scholar A. Szegedi A. Szegedi Departments of DermatologyDermatological Allergology Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 168, Issue 3, 1 March 2013, Pages 656–658, https://doi.org/10.1111/j.1365-2133.2012.11179.x Published: 01 March 2013
Neuropsychological change in encoding and long-term retrieval memory function after lung transplantation
Authors: Michael Neurath, Celina Schlaack, Urte Sommerwerck, Daniel Jokisch, Gerhard Weinreich, Martina Föhring, Markus Kamler, Helmut Teschler, Martha Dlugaj
Journal: European Respiratory Journal (2014)

Background: There are only few studies available that examined memory function after lung transplantation. Especially, little is known about function in relation to duration since transplantation. Therefore, the aim of the present study was to investigate neuropsychological function after lung transplantation.

Methods and Patients: In an ongoing prospective study 50 lung transplanted patients (29 male, mean age 54.9 ± 9 years) on Calcineurininhibitor (Ciclosporin or Tacrolimus) were examined regarding their memory function after lung transplantation. Verbal learning, free recall and recognition were assessed by means of a standardized German verbal memory test (VLMT). We compared the cross-sectional results of patients who were transplanted  5 years ago (n=38, max. 15 years ago).

Results: We did not find significant differences in the immediate free recall memory performance between groups. However, participants who were transplanted <1 year ago showed significantly higher forgetting in the delayed free recall after 30 minutes in comparison to the long-term transplanted patients.

Conclusion: Results provide evidence that there is a slightly higher rate of forgetting concerning retrieval of recently learned verbal information in patients transplanted  5 years ago. The longitudinal follow-up of our participants will allow us to further elucidate the development of memory changes after lung transplantation.
Abstract 15246: High Levels of Nt-probnp Are Associated With Poor Clinical Response to CD34+ Cell Therapy in Patients With Non-ischemic Dilated Cardiomyopathy
Authors: Gregor Poglajen, Gregor Zemljic, Matjaz Sever, Marko Cukjati, Francois Haddad, Joseph C Wu, Bojan Vrtovec
Journal: Circulation (2014)

Background: Although CD34+ cell therapy has been associated with favorable clinical response in non-ischemic dilated cardiomyopathy (DCM), individual patient response is variable. We sought to identify predictors of clinical response in this patient population. Methods: We pooled the data on 77 consecutive patients with DCM who underwent transendocardial CD34+ cell transplantation as a part of several stem cell studies performed at our center from January 2011 until December 2013. All patients received 5-day stimulation with G-CSF; CD34+ cells were selected with apheresis and injected transendocardially guided by electroanatomical mapping. Patients were followed for 6 months and good clinical response was defined as an increase of left ventricular ejection fraction (LVEF) ≥5%. Results: During follow-up, 1 patient died of sudden cardiac death and 1 underwent urgent heart transplantation. Of remaining 75 patients, 36 (48%) had good clinical response and 39 (52%) were poor responders. At baseline, the two gr...
Endothelial Dysfunction and Low-grade Inflammation Are Associated With Greater Arterial Stiffness: The Amsterdam Growth and Health Longitudinal Study (AGAHLS)
Authors: Bas C. van Bussel, Ronald M. Henry, Casper G. Schalkwijk, Isabel Ferreira, Yvo M. Smulders, Fleur Schouten, Jos W. Twisk, Coen D. Stehouwer
Journal: Circulation (2009)